HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 price target.